Oslo, 11 August 2023 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and
reliable provider of high-quality products to hospitals and pharmacies, today
announces its results for the second quarter and first half of 2023. Having
experienced strong growth across the business, Navamedic grew its revenues for
the first half of 2023 by 41.7 per cent, amounting to NOK 245.7 million.

For the first half of 2023, the gross margin was 40.9 per cent, down from 42.9
per cent last year. Adjusted EBITDA (EBITDA less acquisition cost) was NOK 26.3
million, up from NOK 23.3 million in the corresponding period last year, while
the operating result (EBIT) for the first half of 2023 was NOK 9.9 million,
compared to NOK 19.6 million in the same period last year. The result is mainly
explained by significant investments in marketing activities, higher personnel
expenses due to the Impolin acquisition, and M&A-related expenses in the second
quarter of 2023.

Revenues for the second quarter of 2023 was NOK 124 million, gross margin was
40.4 per cent, and adjusted EBITDA for the quarter amounted to NOK 10.5 million
compared to NOK 23.7 million in 2022. The operating result (EBIT) for the second
quarter was negative NOK 4.0 million, compared to NOK 21.9 million last year.

"Since kicking off Navamedic's growth strategy in 2019, we have steadily been
delivering on our goals. The first half of 2023 has been no exception. It has
also been a period where we experienced a lot of market activity in some of our
core treatment areas, ultimately yielding positive outcomes for Navamedic.

"We can look back at a successful first half of the year, having delivered on
our M&A strategy in parallel with product launches and marketing campaigns.  As
we look forward, Navamedic is in an excellent position to achieve its ambitious
growth targets and to continue delivering high-quality products to hospitals and
pharmacies," commented Kathrine Gamborg Andreassen, CEO of Navamedic.

In the period, Navamedic launched an offer for all shares and completed the
acquisition of Sensidose AB, a Sweden-based pharmaceutical company that sell
drugs (Flexilev) in combination with an innovative device for individual dosing
for patients with advanced Parkinson's disease. The addition of Sensidose
broadens Navamedic's RX portfolio and opens up for Navamedic to take up market
share in the European neurology treatment area.

Navamedic will now ramp up commercial efforts by adding Flexilev to its
marketing and distribution channels, starting with the Nordics and a product
launch in Finland. Navamedic will also explore additional European markets and
consider opportunities outside of Europe.

On Friday, 11 August 2023, Navamedic will host a presentation starting at 08.30
CEST. The presentation will take place at Haakon VIIs gate 2 in Oslo, and will
be available to follow via webcast at the following link:
https://navamedic.com/investors/financial-results/

Representatives from Navamedic's management team, CEO Kathrine Gamborg
Andreassen and CFO Lars Hjarrand will host the presentation.

EBITDA and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section of the
attached second-quarter presentation on slide 24.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47917 62 842

E-mail: lars.hjarrand@navamedic.com

About Navamedic

Navamedic ASA is a full-service provider of high-quality healthcare products to
hospitals and pharmacies. Navamedic meets the specific medical needs of patients
and consumers by leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in all the Nordic
countries, the Baltics and Benelux, with sales representation in the UK and
Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (ticker: NAVA). For more information, please visit Navamedic.com.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.